Assignee
NANOCOPOEIA LLC
US·12 granted patents·10 pending applications·49 citations·filing 2015–2024
Top patents by PatentIndex Score
22 records- 0196US11413290B2Amorphous solid dispersions of dasatinib and uses thereofNANOCOPOEIA LLC·Filed 2021·Granted Aug 16, 2022·8 cites·30 claims
- 0296US11324745B2Amorphous solid dispersions of dasatinib and uses thereofNANOCOPOEIA LLC·Filed 2021·Granted May 10, 2022·7 cites·30 claims
- 0396US11298356B1Amorphous solid dispersions of dasatinib and uses thereofNANOCOPOEIA LLC·Filed 2021·Granted Apr 12, 2022·7 cites·30 claims
- 0496US11202778B2Amorphous solid dispersions of dasatinib and uses thereofNANOCOPOEIA LLC·Filed 2021·Granted Dec 21, 2021·9 cites·30 claims
- 0595US11633398B2Amorphous solid dispersions of dasatinib and uses thereofNANOCOPOEIA LLC·Filed 2022·Granted Apr 25, 2023·2 cites·28 claims
- 0695US11389450B2Amorphous nilotinib microparticles and uses thereofNANOCOPOEIA LLC·Filed 2021·Granted Jul 19, 2022·7 cites·28 claims
- 0794US11980619B2Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and usesNANOCOPOEIA LLC·Filed 2022·Granted May 14, 2024·3 cites·18 claims
- 0889US11559485B2Orally disintegrating tablet comprising amorphous solid dispersion of nilotinibNANOCOPOEIA LLC·Filed 2021·Granted Jan 24, 2023·6 cites·30 claims
- 0985US2025032491A1Amorphous nilotinib microparticles and uses thereofNANOCOPOEIA LLC·Filed 2024·Application pending·0 cites
- 1082US12053471B2Amorphous nilotinib microparticles and uses thereofNANOCOPOEIA LLC·Filed 2023·Granted Aug 6, 2024·0 cites·22 claims
- 1182US12016861B2Amorphous nilotinib microparticles and uses thereofNANOCOPOEIA LLC·Filed 2022·Granted Jun 25, 2024·0 cites·22 claims
- 1282US11998548B2Amorphous nilotinib microparticles and uses thereofNANOCOPOEIA LLC·Filed 2022·Granted Jun 4, 2024·0 cites·19 claims
- 1380US12029740B2Amorphous nilotinib microparticles and uses thereofNANOCOPOEIA LLC·Filed 2022·Granted Jul 9, 2024·0 cites·24 claims
- 1479US2022105035A1Amorphous solid dispersions of dasatinib and uses thereofNANOCOPOEIA LLC·Filed 2021·Application pending·0 cites
- 1575US2023390791A1Electrohydrodynamic atomization nozzle emitting a liquid sheetNANOCOPOEIA LLC·Filed 2023·Application pending·0 cites
- 1670US2023372325A1Amorphous cabozantinib particles and uses thereofNANOCOPOEIA LLC·Filed 2023·Application pending·0 cites
- 1769US2025025463A1Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereofNANOCOPOEIA LLC·Filed 2024·Application pending·0 cites
- 1864US2023157948A1Orally disintegrating tablet comprising amorphous solid dispersion of nilotinibNANOCOPOEIA LLC·Filed 2023·Application pending·0 cites
- 1962US2022378788A1Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereofNANOCOPOEIA LLC·Filed 2022·Application pending·0 cites
- 2061US2020179963A1Electrohydrodynamic atomization nozzle emitting a liquid sheetNANOCOPOEIA LLC·Filed 2020·Application pending·0 cites
- 2141US2016235677A1Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturationNANOCOPOEIA LLC·Filed 2015·Application pending·0 cites
- 2236US2016175881A1Electrospray methods, electrospray systems, and methods of forming crystalline particlesNANOCOPOEIA LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NANOCOPOEIA LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →